論文

査読有り
2013年6月

Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin

CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Yutaka Ueda
  • ,
  • Takayuki Enomoto
  • ,
  • Shinya Matsuzaki
  • ,
  • Eiji Kobayashi
  • ,
  • Toshihiro Kimura
  • ,
  • Kiyoshi Yoshino
  • ,
  • Masami Fujita
  • ,
  • Tateki Tsutsui
  • ,
  • Tadashi Kimura

71
6
開始ページ
1411
終了ページ
1416
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s00280-013-2138-5
出版者・発行元
SPRINGER

The aim of the present study was to investigate, in ovarian carcinoma cases, the predictive association between the treatment-free interval (TFI) after an initial paclitaxel plus carboplatin (TC) therapy and the subsequent effectiveness of a second-line taxane-containing chemotherapy.
Patients with a TFI < 6 months from the first-line TC therapy were treated with a combination chemotherapy using docetaxel and irinotecan; patients with a TFI a parts per thousand yen 6 months were retreated with the same regimen as the initial TC therapy. The clinical data of these patients were retrospectively analyzed for this study.
The response rate of those with a TFI equal to 6-12 months was greater than that of those with a TFI < 6 months (p = 0.014) and less than that of those with a TFI > 12 months (p = 0.012). The progression-free survival of the cases with TFI equal to 6-12 months was longer than that of those with TFI < 6 months (p = 0.012) and shorter than that of those with TFI > 12 months (p = 0.0011). Overall survival of cases with a TFI equal to 6-12 months was longer than that of those with TFI < 6 months (p = 0.012) and shorter than that of those with TFI > 12 months (p = 0.0005).
The effectiveness of using a second-line taxane-containing chemotherapy was shown to be predictable by the TFI after the first-line taxane-containing chemotherapy, implying that the theory of 'taxane-sensitivity' may be applied for second-line chemotherapy in the same way as that of 'platinum-sensitivity'.

リンク情報
DOI
https://doi.org/10.1007/s00280-013-2138-5
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/23515753
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000319751400003&DestApp=WOS_CPL
ID情報
  • DOI : 10.1007/s00280-013-2138-5
  • ISSN : 0344-5704
  • PubMed ID : 23515753
  • Web of Science ID : WOS:000319751400003

エクスポート
BibTeX RIS